1. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Issue 8 (13th May 2020) Authors: Kedor, Claudia; Listing, Joachim; Zernicke, Jan; Weiß, Anja; Behrens, Frank; Blank, Norbert; Henes, Joerg Christoph; Kekow, Joern; Rubbert-Roth, Andrea; Schulze-Koops, Hendrik; Seipelt, Eva; Specker, Christof; Feist, Eugen Journal: Annals of the rheumatic diseases Issue: Volume 79:Issue 8(2020) Page Start: 1090 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Issue 1 (28th July 2021) Authors: Redeker, Imke; Albrecht, Katinka; Kekow, Joern; Burmester, Gerd Rüdiger; Braun, Juergen; Schäfer, Martin; Zink, Angela; Strangfeld, Anja Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 1(2022) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗